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Anti-nuclear antibodies (ANA) are fundamental for the
diagnosis of autoimmune diseases, and have been
determined by indirect immunoﬂuorescence assay (IIFA)
for decades. As the demand for ANA testing increased,
alternative techniques were developed challenging the
classic IIFA. These alternative platforms differ in their
antigen proﬁles, sensitivity and speciﬁcity, raising
uncertainties regarding standardisation and interpretation
of incongruent results. Therefore, an international group
of experts has created recommendations for ANA testing
by different methods.
Two groups of experts participated in this initiative.
The European autoimmunity standardization initiative
representing 15 European countries and the International
Union of Immunologic Societies/World Health
Organization/Arthritis Foundation/Centers for Disease
Control and Prevention autoantibody standardising
committee. A three-step process followed by a Delphi
exercise with closed voting was applied.
Twenty-ﬁve recommendations for determining ANA
(1–13), anti-double stranded DNA antibodies (14–18),
speciﬁc antibodies (19–23) and validation of methods
(24–25) were created. Signiﬁcant differences between
experts were observed regarding recommendations
24–25 (p<0.03). Here, we formulated recommendations
for the assessment and interpretation of ANA and
associated antibodies. Notably, the roles of IIFA as a
reference method, and the importance of deﬁning
nuclear and cytoplasmic staining, were emphasised,
while the need to incorporate alternative automated
methods was acknowledged. Various approaches to
overcome discrepancies between methods were
suggested of which an improved bench-to-bedside
communication is of the utmost importance. These
recommendations are based on current knowledge and
can enable harmonisation of local algorithms for testing
and evaluation of ANA and related autoantibodies. Last
but not least, new more appropriate terminologies have
been suggested.
INTRODUCTION
Autoantibodies are a hallmark of autoimmunity, of
which anti-nuclear antibodies (ANA) have taken the
centre stage for the past 60 years. The term ANA is
now outdated and even confusing as this historical
label has come to encompass antibodies directed at
various cellular compartments including nuclear con-
stituents, components of the nuclear envelope,
mitotic spindle apparatus, cytosol, cytoplasmic orga-
nelles and cell membranes. Detection of anti-cellular
antibodies of the ANA family is pivotal to the diagno-
sis of many autoimmune diseases.1 2 Moreover, spe-
ciﬁc antibodies of the ANA family may present years
before the appearance of overt disease, and for some
conditions serological assays can provide useful infor-
mation on the likelihood of clinical course or compli-
cations (eg, inﬂammatory myopathies, systemic lupus
erythematosus (SLE)). Hence, the determination of
ANA may enable the prediction, diagnosis and activ-
ity determination of certain autoimmune diseases.3 4
ANA detection by the indirect immunoﬂuores-
cence assay (IIFA) was ﬁrst described in 1950 by
Coons and Kaplan.5 This ‘gold’ standard technique
is at present performed using HEp-2 cells or var-
iants of this cell line (ie, HEp-2000).6 The IIFA
requires a laborious process consisting of serial
dilutions of positive sera, visual determination of
the staining pattern, followed by a second test in
which antigen speciﬁcity is determined.7 8 IIFA
entails substantial technical expertise and while it is
considered the ‘gold’ standard, it is only as good as
the laboratory that performs this assay. Another
limitation of IIFA is its lack of speciﬁcity. Indeed,
depending on demographics, the population being
studied, serum dilution, the cut-off used and other
variables of this assay, up to 25% of sera from
apparently healthy individuals can be ANA posi-
tive.9–14 Noteworthy, in the general population
some individuals with a positive ANA test by IIFA
do not have an autoimmune disease and are
unlikely to develop one.
Agmon-Levin N, et al. Ann Rheum Dis 2013;0:1–7. doi:10.1136/annrheumdis-2013-203863 1
Recommendation
 ARD Online First, published on October 14, 2013 as 10.1136/annrheumdis-2013-203863
Copyright Article author (or their employer) 2013. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
 group.bmj.com on November 19, 2013 - Published by ard.bmj.comDownloaded from 
In past decades, the demand for ANA testing has increased
remarkably, raising the need for high throughput in service
laboratories. These changes resulted in a technical evolution and
the development of novel diagnostic platforms including the
ELISA, addressable laser bead immunoassay, chemiluminescence
immunoassay, ﬂuorescent-enzyme immunoassay, line immunoas-
says10 and others.8 15 16 The latter are based on a limited
number of puriﬁed and/or synthetic autoantigens. For details on
the methodology see the supplementary material (available
online only). The test characteristics of these novel assays are
strongly distinct from the ANA–IIFA. Debates regarding ANA
determination by different tools have recently resulted in a pos-
ition statement of the American College of Rheumatology
(ACR), claiming that IIFA is the ‘gold’ standard for ANA detec-
tion, and that alternative methods should demonstrate perform-
ance as good as IIFA (http://www.rheumatology.org/practice/
clinical/position/ana_position_stmt.pdf). This position statement
is primarily based on the high sensitivity of IIFA for certain
autoimmune diseases such as SLE and to a lesser extent systemic
sclerosis (SSc). Moreover, it is strongly supported by the histor-
ical inclusion of the ANA, as performed by IIFA, as a criterion
of certain diseases. Unfortunately, IIFA speciﬁcity and sensitivity
is relatively low for other diseases (eg, inﬂammatory myop-
athies) and its technical limitations as detailed above are yet to
be overcome.
Therefore, an international group of experts (laboratory spe-
cialists, scientists and clinicians) have developed a set of recom-
mendations for the appropriate assessment and interpretation of




Two groups of experts participated in this initiative. The
European autoimmunity standardization initiative (EASI) was
formed a decade ago. This forum was assembled with the aims
of improving the diagnosis of systemic autoimmune-rheumatic
diseases (SARD), the rationale of autoantibody testing and to
stimulate interactions between clinical and laboratory specialist
while considering cost-effectiveness and novel techniques
(http://www.easi-network.com/). In this study expert teams from
15 European countries, namely Italy, Germany, The
Netherlands, France, UK, Sweden, Belgium, Finland, Norway,
Switzerland, Austria, Spain, Ukraine, Portugal and Israel partici-
pated. Each national EASI team consists of clinicians, laboratory
specialists and scientists, dedicated to the ﬁeld of SARD. The
ﬁnal vote for each team was the average score of all participants
from the same country.
The International Union of Immunologic Societies/World
Health Organization/Arthritis Foundation/Centers for Disease
Control and Prevention (IUIS/WHO/AF/CDC) committee for
the standardisation of autoantibodies in rheumatic and related
diseases (http://www.autoab.org) was established in the early
1980s, and is also afﬁliated with the ACR. The establishment of
this group was primarily based on the recognised needs for ref-
erence human autoimmune sera that were critical for academic,
clinical and industrial laboratories, as well as the need to com-
municate to the wider stakeholder community and to facilitate
ongoing activities in continuing the mission in autoantibody
standardisation.17
Development of recommendations
A three-step process was applied for creating these recommen-
dations for the determination and interpretation of ANA and
related antigen-speciﬁc antibody testing. First, 31 preliminary
statements were generated by the EASI forum, based on previ-
ous algorithms from Italy, Germany, The Netherlands and the
ACR. Following review of the literature, these recommendations
were subjected to open comments by the EASI teams and
grading by each EASI team on a scale of 1–5 (ie, full agreement
to no agreement, respectively). Thereafter, based on the results
of the ﬁrst stage, the EASI forum reformulated a new set of 25
recommendations. These were subjected to review and modiﬁca-
tions by both the EASI teams and the IUIS/WHO/AF/CDC com-
mittee members.
In the third stage a Delphi exercise with closed voting fol-
lowed. During this exercise the ﬁnal 25 recommendations were
separately voted on and given a score from 0 (absolutely no
agreement with the recommendation) to 10 (maximal support
for the recommendation). The means and SD scores of all parti-
cipants were calculated to determine the level of agreement for
each recommendation. Therefore, the highest agreement is
deﬁned by the highest mean score accompanied by the lowest
SD. Separate scores for the voting by the EASI groups versus the
IUIS members were assessed using the t test (p<0.05 was con-
sidered signiﬁcant).
RESULTS
Twenty-ﬁve recommendations were formulated in this study and
divided into four subgroups. The ﬁrst 13 recommendations were
dedicated to the ANA test (1–13), ﬁve to the determination of
anti-double stranded DNA antibodies (14–18) and ﬁve to the
determination of speciﬁc antibodies including those directed to
extractable nuclear antigens (ENA; 19–23). Recommendations
24–25 addressed the need for local validation of different
methods. Each recommendation was graded by a Delphi voting
score composed of voting by the EASI and the IUIS groups. Scores
are presented as the mean±SD of the entire forum (table 1).
Signiﬁcant statistical differences between the voting of the
EASI teams and the IUIS members were observed only regarding
recommendations 24 and 25, which received the grades 8.3±3
vs 10±0 and 7.4±2.9 vs10±0, respectively (p<0.03).
The broad spectrum of nuclear and cytoplasmic staining pat-
terns, in relation to antibody speciﬁcity and associated disease,
is speciﬁed in table 2.
DISCUSSION
In this study we formulated 25 recommendations intended to
clarify and standardise clinical and technical aspects pertaining
to the determination of ANA and related antigen-speciﬁc anti-
bodies. In addition, key principles regarding terminology, dis-
crepancies between methods and communication between
laboratory and clinical specialists were addressed.
Terminology
The terms ‘anti-nuclear antibodies’ (ANA) and ‘extractable
nuclear antigens’ (ENA) are no longer technically correct and
do not cover the entire spectrum of relevant autoantibodies.
‘ANA’ may now detect antibodies directed against nuclear and
non-nuclear elements (see recommendation 13), while ‘ENA’
may refer to antigens that are neither extractable nor nuclear.
Therefore, one may suggest changing these outdated terms to
appropriate ones, such as anticellular antibodies and speciﬁc
antibodies, respectively. Such a change in nomenclature requires
broad agreement within the medical community and an adjust-
ment period, as most manuscripts and textbooks utilise these
‘classic terms’. In the current manuscript we have used the
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traditional term ANA and ENA, with the appreciation that they
refer to a broader antigen speciﬁcity.
Discrepancy between platforms
The increasing demand for ANA tests led to the development of
new automated methods for their detection, some of which
probably represent the future of diagnostic serology.18 However,
the inconsistencies between methods are currently a burden on
those who perform and interpret these tests. For this reason, we
have addressed the concepts of discordant results and communi-
cation between laboratory and clinical specialists. As a general
rule, if discrepancy between methods is observed, especially in
the setting of high clinical suspicion, another approved and vali-
dated diagnostic platform should be utilised. Notably, in certain
cases, choosing another platform or deciding which method is
preferred may require a collaborative assessment of clinicians
and laboratory specialists.19 For example, the use of
anti-dsDNA antibody titration for monitoring SLE activity is
better achieved by using a quantitative assay such as ELISA or
the Farr assay, whereas at the time of the diagnosis, the
immunoﬂuorescence on Crithidia luciliae immunoﬂuorescence
test (CLIFT) or the Farr assays may offer the best speciﬁcity.20
Discrepancies between clinical assessment and laboratory results
have also been reported. It is our recommendation that in cases
of high clinical suspicion a physician request for the determin-
ation of speciﬁc antibodies should be granted, irrespective of
the result of previous tests. For instance, speciﬁc antibodies
directed against Jo-1, ribosomal P or SS-A/Ro may be detected
in patients who are ANA negative by IIFA. In this regard, one
may consider the possibility that for an individual patient ser-
ology may change over time. Another important issue at present
concerns the use of ANA/anti-DNA testing as inclusion criteria
for clinical trials that may require the use of several platforms
balancing speciﬁcity versus sensitivity.




1 The diagnosis of SARD requires a panel of specific laboratory tests (ie, ANA, anti-dsDNA and anti-ENA antibodies) 9.6±0.9
2 ANA, anti-dsDNA and anti-ENA testing should be included in the autoantibodies detection as part of the diagnostic work-up of SARD as well as some
other autoimmune diseases (table 2)
9.9±0.2
3 The detection of ANA is the first level test for laboratory diagnosis of SARD 9.8±0.4
4 ANA testing is primarily intended for diagnostic purposes, and not for monitoring disease progression 9.6±0.6
5 The IIFA* is the reference method for ANA screening. Alternative assays can be used while keeping in mind that false negative and false positive ratio
of these methods may be different. Thus, if the clinical suspicion is strong and the alternative method is negative, it is mandatory to perform IIFA
9.7±0.6
6 Diagnostic laboratories should specify the methods used for detecting ANA when reporting their results 9.4±0.9
7 Tests based on a (restricted) mixture of defined nuclear antigens should not be referred to as ANA test or ANA screen 9.7±0.5
8 Laboratories using in-house assays for detecting ANA, as well as anti-dsDNA and specific anti-ENA antibodies, should standardise each assay according
to international standards (eg, WHO, CDC/IUIS)
9.7±0.5
9 For ANA screening by IIFA the conjugate should consist of fluorochrome-labelled anti-human IgG-specific secondary antibodies 9.2±1.2
10 A proper ANA–IIFA is dependent on reagents, equipment and other local factors, thus the screening dilution should be defined locally. An abnormal
ANA should be the titre above the 95th percentile of a healthy control population. In general, a screening dilution of 1 : 160 on conventional
HEp-2(000) substrates is often suitable for the detection of ANA in adult populations being evaluated for SARD
9.0±1.4
11 In the case of a positive ANA test, it is recommended that the pattern and the highest dilution to demonstrate reactivity be reported 9.4±0.9
12 ANA–IIFA patterns should be reported according to standardised terminology (table 2) 9.7±0.4
13 Besides nuclear patterns also cytoplasmic and mitotic apparatus patterns should be reported and specified when possible (table 2) 9.5±1.0
14 If ANA result is positive, testing for anti-dsDNA antibodies is advised when there is clinical suspicion of SLE 9.7±0.4
15 For anti-dsDNA antibody determination, the Farr assay and the CLIFT offer high clinical specificity. Alternative methods may yield lower specificity and,
if so, it is recommended that positive results obtained by these methods be confirmed by CLIFT or Farr assay—and be reported separately
8.0±2.5
16 The method used for anti-dsDNA antibody detection should be included in the test result 9.4±0.7
17 Results of anti-dsDNA antibody detection should be reported quantitatively (or semiquantitatively for CLIFT) 9.7±0.4
18 For monitoring of SLE disease activity by quantitative determination of anti-dsDNA antibodies the same method should be used 9.9±0.3
19 In case of a positive ANA test during the diagnostic work-up (depending on pattern, titre and/or clinical setting), it is recommended to perform specific
tests for anti-ENA antibodies (table 2)
9.8±0.3
20 For anti-ENA antibodies detection the method used should be reported. In the case of discrepancy with IIFA or with clinical suspicion, the use of an
additional method should be considered
9.5±0.5
21 Results of assays for antibodies to specific ENA should be reported separately (including negative results); if the result of a screening assay is reported
as negative, it is sufficient to communicate which ENA are present in that assay
9.8±0.4
22 Quantitative determination of positive anti-RNP antibodies is recommended in case of a clinical suspicion of mixed connective tissue disease 8.2±2.7
23 In case of high clinical suspicion the physician request for determination of antibodies to specific ENA should be granted, irrespective of the result of
the ANA test. For instance, anti-Jo-1 antibodies for clinically suspected IM, anti-ribosomal P for SLE or anti-SS-A/Ro antibodies for congenital heart
block/neonatal lupus/Sjögren’s syndrome/subacute cutaneous lupus
9.9±0.1
24 Each laboratory should verify the recommended cut-off for kits used to determine ANA. It is recommended to use age and gender matched sera from
healthy subjects from the general local population; cut-offs should be defined as the 95th percentile
8.4±2.8
25 Each laboratory should verify the recommended cut-off for kits used to determine anti-dsDNA and anti-ENA antibodies. It is recommended to use an
adequate number of samples from patients with the appropriate autoimmune diseases, disease controls and healthy controls; cut-offs should be
defined using ROC curve analysis
7.6±2.9
*See supplementary materials (available online only) for further information on the methodology of immunoassays.
ANA, anti-nuclear antibodies; CDC, Centers for Disease Control and Prevention; CLIFT, Crithidia luciliae immunofluorescence test; dsDNA, double-stranded DNA; ENA, extractable nuclear
antigens; IIFA, indirect immunofluorescent assay; IM, inflammatory myopathies; IUIS, International Union of Immunologic Societies; RNP, ribonucleoproteins; ROC, receiver operating
characteristic; SARD, systemic autoimmune rheumatic diseases; SLE, systemic lupus erythematosus; WHO, World Health Organization.
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Communication between the laboratory bench and the clinic
This is an all-embracing issue detailed in many of our recom-
mendations (ie, 7, 11, 12, 13, 14, 16, 19, 20 and 21). Notably,
many clinicians are unaware of the speciﬁc method or the differ-
ences between methods used for ANA detection, and may erro-
neously apply the test characteristics of IIFA to other methods.
Therefore, by and large the autoimmune laboratory should
specify each method used. In addition, in the case of ANA
detection by IIFA, titres and patterns obtained should be
reported. If multiple methods are being used either for ANA,
anti-dsDNA or other antigen-speciﬁc autoantibodies, the results
obtained by each method should be reported separately. In add-
ition, if further testing is advised (eg, the determination of
anti-dsDNA in samples with high titre homogenous ANA by
IIFA) a laboratory comment may be included as detailed below.
The recommendations
The ﬁrst subgroup of recommendations (1–13) is dedicated to
ANA screening at the ﬁrst level of diagnosis.1 Most of our
knowledge regarding ANA screening is based on data obtained
by IIFA. As such, the prevalence of ANA–IIFA among SLE
patients is expected to be above 95%, while a lower prevalence
may be detected using methods that rely on a limited number of
antigens.7 8 Furthermore, ANA can be detected in patients with
autoimmune, malignant or infectious diseases as well as in
healthy subjects. Hence, the performance of any ANA assay is
highly dependent on its pre-test probability, and interpretation of
results should be governed by clinical circumstances.1 18 In these
recommendations, like others, we have recognised IIFA on
HEp-2 (or HEp-2000) to be the reference method of choice for
ANA screening.6 21 However, we have also acknowledged the
limitations of IIFA, including the time required for its perform-
ance and the necessity of highly qualiﬁed laboratory personnel.
The latter raises the urgent need for training programmes on
IIFA performing and autoimmune serology interpretation.22 In
contrast, the alternative automated methods (see supplementary
material, available online only) have come into common use,
especially in high-throughput laboratories. These methods are
Table 2 IIFA nuclear/cytoplasmic patterns detected on HEp-2 substrates and related antigens/diagnosis
Most commonly recognised patterns
Nuclear patterns Related antigens Related diagnosis
Homogeneous dsDNA, histones, chromatin/nucleosomes, HMG SLE, drug induced SLE/vasculitis, JIA
Coarse speckled U1-SnRNP, U2–6 snRNP (Sm), nuclear matrix MCTD, SLE, Raynaud, SSc, SS, UCTD
Fine speckled SSA/Ro, SSB/La, Topo-1, common to many antigens SLE, SS, SSc, IM, MCTD
Centromere Kinetochore: CENP-A, B, C, F SSc (limited), Raynaud’s
Nucleolar PM/Scl, RNA-polymerase, URNP, U3-RNP, To/Th, B23 phosphoprotein/
numatrin
SSc, Raynaud’s, IM, overlap
Cytoplasmic patterns Related antigens Related diagnosis
Diffuse RibP, Jo-1, other tRNA synthetases, SRP SLE, IM
Fine speckled Jo-1, SRP, PDH (mitochondria) IM, DM, PBC, interstitial lung disease
Less commonly recognised patterns
Nuclear patterns Related antigens Related diagnosis
Peripheral/rim or nuclear envelope Lamins, LAP1/2 gp210, nucleoporin p62; nuclear envelope and nuclear pore
complex antigens
SLE, RA, PBC, IM autoimmune liver diseases
Dense fine speckled DFS70/LEDGF-P75 Healthy subjects and other inflammatory
conditions
Pleomorphic cell cycle speckled (PCNA) Auxiliary protein proliferating cell nuclear antigen: elongation factor of DNA
polymerase delta
SLE, lymphoproliferative diseases, SS
Nucleolar (clumpy) U3-SnRNP (fibrillarin) SSc
Multiple/few nuclear dots Sp100, PML bodies, p80-coilin PBC, CAH, SS
Centrosome/centriole (formerly:spindle
apparatus)
Enolase, ninein, pericentrin SSc, Raynaud’s, inflammatory disease
MSA (mitotic spindle) NuMA/centrophilin RA, inflammatory conditions; pneumonia
(mycoplasma)
Cytoplasmic patterns Related antigens Related diagnosis
Discrete speckled Endosome (early endosome antigen 1), GW/Processing bodies, multivesicular
bodies/lysosomes
Neurological conditions, SS, SLE, RA, PBC,
UCTD
Golgi complex Golgi proteins/golgins: giantin, golgin 245, golgin 110, golgin 97, golgin 95,
others
SLE, SS, RA, overlap syndromes, cerebellar
ataxia
Cytoplasmic fibres Actin, cytokeratin, tropomyosin, vimentin CAH, DM, infections and other inflammatory
diseases
Within the many patterns that can be distinguished the ones specified in the upper part of the table are the most commonly recognised. The relationship between pattern and antigen
specificity may differ in certain conditions. Similarly, the specific antigens marked in bold are the most commonly detected by reflex testing, although other antigens may be of
importance in different clinical conditions. Less common pattern are specified in the lower part of this table.
CAH, chronic autoimmune hepatitis; CENP, centromere protein; DFS, dense fine speckled; DM, dermatomyositis; dsDNA, double-stranded DNA; GW, glycine—tryptophan; HMG, high mobility
group; IM, inflammatory myopathies; JIA, juvenile idiopathic arthritis; MCTD, mixed connective tissue disease; MSA, mitotic spindle; NuMA, nuclear mitotic apparatus; PBC, primary biliary
cirrhosis; PDH, pyruvate dehydrogenase; PM/Scl, polymyositis/scleroderma; RA, rheumatoid arthritis; RibP, ribosomal P protein; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; SRP,
signal recognition particle; SS, Sjögren’s syndrome; SSc, systemic sclerosis; Topo-1, topo-isomerase 1; tRNA, transfer RNA; UCTD, undifferentiated connective tissue disease.
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simple to operate and may have the added value of better recog-
nition of speciﬁc antibodies. Alas, they often lack sufﬁcient
sensitivity for certain diseases (ie, SLE and SSc)23–27 (recommen-
dation 5). Considering the pro and cons, we have included the
alternative assays in our recommendations as long as the platform
being used is clearly speciﬁed (recommendation 6) and the result
is not referred to as ‘ANA test’ or ‘ANA screen’, which are typic-
ally associated with ANA testing by IIFA (recommendation 7).
From the laboratory perspective, standardisation of IIFA is
vital, and several variables of this method have been speciﬁed.
The recommended substrate for ANA–IIFA derives from a
human epithelial cell line (HEp-2 or HEp2000) and should
contain a sufﬁcient number of mitotic cells to enable adequate
pattern recognition. Low positive control samples as well as an
internal cut-off control, randomly distributed in distinct runs,
may enable continuous training of technicians. The secondary
detection antibody (conjugate) should consist of ﬂuorochrome-
labelled anti-human IgG-speciﬁc antiserum (recommendation 9),
either FITC or another validated new-generation ﬂuorochrome.
A special consideration, at a regular interval, to the ﬂuorochrome
potency and ultraviolet bulb strength was suggested. Another
variable of ANA testing is the screening dilution of sera.6 21
Following review of the literature and many discussions among
the committee experts, it was agreed that the optimal screening
dilution must be deﬁned locally, and the titre related to the 95th
percentile of healthy controls considered the optimal screening
dilution. In cases of uncertainty, while taking into consideration
sensitivity, speciﬁcity and cost (ie, wells on slides, technician
time, other reagents), we have pointed out that a screening dilu-
tion of 1 : 160 was often found to be the most suitable for the
evaluation of adult patients.6 21 In an international study, ANA
was documented in 31.7% of healthy subjects at 1 : 40 serum
dilution, 13.3% at 1 : 80 and 5.0% at 1 : 160.21 Conversely, at
1 : 160 dilution the sensitivity for SARD is not perfect and a
negative result does not exclude disease. Notably, no consensus
could be achieved among experts regarding the screening dilu-
tion for children (<16 years), for which some use a dilution of
1 : 40, or the need for further dilution once a positive result was
obtained. Previously, it was generally accepted that individuals
without autoimmune disease would present with lower serum
levels while high-titre ANA are clinically more signiﬁcant.12
However, there is ample evidence that low-titre ANA may be sig-
niﬁcant and that titres following the screening threshold of 1 : 80
or 1 : 160 have no bearing on diagnosis or disease activity.7 15
Patterns of ANA by IIFA reﬂect the topographic distribution of
target autoantigens (recommendations 11, 12)28 and may convey
signiﬁcant information about antibody speciﬁcity (table 2).29 The
role of cell cycle dynamics (ie, interphase, mitotic) in deﬁning pat-
terns is of great importance, especially for complex patterns
related to autoantigens that exhibit a dynamic behaviour along the
cell cycle, such as centromere protein (CENP)-F, NuMA-1 and
topoisomerase-1.30–32 The recognition of both nuclear and cyto-
plasmic patterns enables ‘reﬂex testing’ (ie, testing for speciﬁc anti-
bodies depending of the pattern) and improves the utility of the
serological evaluation (recommendation 13).1 28
Antibodies directed against dsDNA are a key marker for diag-
nosis and follow-up of patients with SLE33 34 (recommendations
14–18). Theoretically, if ANA–IIFA is negative one should not
proceed to deﬁning anti-dsDNA antibodies,35 36 although if
clinical suspicion of SLE is substantial anti-dsDNA antibodies
assessment may be requested by the clinician. On the other
hand, certain IIFA patterns (eg, homogenous) are suggestive of
anti-dsDNA antibody (table 2).37 Regrettably, in most laborator-
ies ‘reﬂex testing’ cannot be performed unless requested;
thereby the addition of a note to the ANA–IIFA result should be
considered (eg, ‘This pattern may represent antibodies directed
to DNA or chromatin components. Further tests are advised if
there is a clinical suspicion of systemic lupus erythematosus’).
The appropriate method of anti-dsDNA antibodies determination
is still a matter of debate. The Farr assay and the CLIFToffer high
clinical speciﬁcity (recommendation 15).35 38 In point of fact, the
Farr assay is the one ‘speciﬁc’ for anti-dsDNA related to SLE diag-
nosis, owing to its ability to detect high avidity antibodies.
However, both assays have substantial drawbacks. The Farr assay
requires the use of radioisotopes, and may detect anti-dsDNA anti-
bodies induced by drugs (ie, anti-tumour necrosis factors)39 while
the CLIFT is not quantitative and is accompanied by relatively low
sensitivity. Alternative methods for anti-dsDNA detection have
recently been developed. Most of them provide high sensitivity
but are hampered by lower speciﬁcity and lack of correlation with
each other.38 40 Reﬂecting on these aspects, we have recom-
mended that positive results obtained by these alternative methods
be conﬁrmed by CLIFTor Farr assay. Nonetheless, if discrepancy
between methods is observed both results should be reported. In
such cases a careful explanation should be provided by the labora-
tory and the ﬁnal interpretation should take into consideration the
clinical scenario and the ANA–IIFA pattern. Last but not least, for
follow-up of anti-dsDNA titres a quantitative method (ie, not
CLIFT) (recommendations 16, 17), preferably by the same
method and performed by the same laboratory, is recommended
(recommendation 18).
The identiﬁcation of antibody speciﬁcity to nuclear and cyto-
plasmic antigens may further differentiate between diseases41–44
(table 2; recommendation 19). Although there is a clear correl-
ation between IIFA patterns and antigen speciﬁcity (table 2), this
association is not perfect and antigen speciﬁcity cannot be
deduced from the IIFA pattern alone. Furthermore, disagreements
between methods to detect speciﬁc antibodies and/or IIFA patterns
were reported.44–46 In these cases an alternative method can be
employed (recommendations 1, 20, 21). In addition, unlike
anti-dsDNA, the coexistence of negative ANA by IIFA and sero-
positivity for speciﬁc antibodies by solid phase assay is not rare (ie,
anti-SSA/Ro).47 Thus, a physician request to determine speciﬁc
antibodies should be granted, irrespective of ANA–IIFA (recom-
mendation 23). Notably, another aspect concerning anti-SSA/Ro
antibody is the detection of its variants directed at Ro60 and
Ro52/TRIM21, as some tests currently in use include only the
Ro60 antigen. Detection of anti-SSA/Ro is recommended in differ-
ent scenarios including counselling of patients with autoimmune
disease who desire a pregnancy. The latter are mainly related to
anti-Ro52/TRIM21 antibodies. Therefore, specifying the antigen
used and evaluation of both anti-Ro52 and anti-Ro60 should be
considered. The importance of speciﬁc antibody levels is still a
matter of debate. In particular, the signiﬁcance of anti- ribonucleo-
protein levels (recommendation 22) data are lacking regarding
levels determined by current methods in comparison to the histor-
ical haemaglutination test used for the mixed connective tissue
disease criterion.48
The fourth subgroup of our recommendations addresses the
issue of local validation of methods (24, 25). Both recommenda-
tions were fully accepted by the IUIS group and signiﬁcantly less
by the EASI teams. This divergence between experts may be
explained by the different regulations applied in the different
countries, namely in America and Canada local validation is fre-
quently required by the authorities. Nevertheless, as the list of
available methods is bound to increase, it is highly likely that in
the years to come veriﬁcation of assays will be an important
feature of autoimmune laboratories worldwide.
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CONCLUSIONS
Deﬁning anticellular antibodies is an essential component of the
evaluation of patients with autoimmune diseases. The wide
array of methods for their determination prompted questions
and debate among laboratory personnel, clinicians, as well as
co-authors of this manuscript. Therefore, in this study we have
offered recommendations that are applicable and may facilitate
the design of local algorithms for ANA detection. We have
pointed out that the changes in the ﬁeld of autoimmune diag-
nostics necessitate dedicated training of those who demand,
perform and interpret the results. Therefore, in parallel to deﬁn-
ing new autoantibodies and the development of new platforms
an urgent need for training programmes for clinician, techni-
cians and the industry has been recognised. Last but not least,
further studies are required to address issues such as the local
validation of platforms, signiﬁcance of titres and patterns
among different populations (ie, children), and different stages
of diseases (ie, pre-clinical vs fully established; active vs quies-
cent) and the role of novel automated IIFA methods that may
overcome many limitations of the manual form of this assay.
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